Title:
Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Indication:
Hematologic Malignancy
Location:
Texas Oncology-Amarillo Cancer Center
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Anal Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Biliary Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II/III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Biliary Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma
View
Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
Indication:
Biliary Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Bladder Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Bladder Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
Ph2 Sub Mosunetuzumab B-cell malig
View
Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
Indication:
Blood Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Breast Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors
View
Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)
Indication:
Breast Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I/II
Title:
Observational Study of patients initiating T-Dxd in HER2+ unresectable mBC (RESPOND)
View
Description: A multi-center multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+ and HER2-low unresectable and/or metastatic breast cancer (DESTINY BREAST- RESPOND) (D9673R00025)
Indication:
Breast Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Breast Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
View
Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)
Indication:
Breast Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Cervical Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Cervical Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Cervical Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Colon Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Colon Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors
View
Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I/II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Esophageal Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Gastric Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
PATHFINDER 2 Early Detection Test
View
Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)
Indication:
Hematologic
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Hematologic
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Kidney Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Leukemia
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Liver Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Liver Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
STAR Ph3 Adj Selp St1B/3 RET+ NSCLC
View
Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)
Indication:
Lung Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Lung Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
View
Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)
Indication:
Lung Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC
View
Description: A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)
Indication:
Lung Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I/II
Title:
Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors
View
Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)
Indication:
Lung Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I/II
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Lung Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II/III
Title:
STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR
View
Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004
Indication:
Lung Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
Ph3 Dato-DXd + Durva + Carbo v. Pembro + plat chemo in 1L mNSCLC
View
Description: A Phase III Randomised Open-label Multicentre Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)
Indication:
Lung Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Lung Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph
View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
Ph2 Sub Mosunetuzumab B-cell malig
View
Description: AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
Indication:
Lymphomas
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Melanoma
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors
View
Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)
Indication:
Mesothelioma
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I/II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Myelodysplastic Syndrome
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Myelomas
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors
View
Description: Phase 1/2 Study of PRO1184 in Patients with Locally Advanced and/or Metastatic Solid Tumors (PRO1184-001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I/II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II/III
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Prostate Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Prostate Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Prostate Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Rectal Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Renal Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Renal Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Skin Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C
View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I/II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Solid Tumors
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
PATHFINDER 2 Early Detection Test
View
Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)
Indication:
Solid Tumors
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes
View
Description: A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007)
Indication:
Solid Tumors
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Solid Tumors
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Testicular Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test
View
Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)
Indication:
Thyroid Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: IV
Title:
STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)
View
Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II/III
Title:
Ph2 SKB264 + Pembro in Select Solid Tumors
View
Description: A multicenter open-label phase 2 basket study to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with selected solid tumors (SKB264-II-06)
Indication:
Urothelial Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Uterine Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
DETECT-ASCEND 2 Plasma Based Test
View
Description: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing - Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)
Indication:
Vulvar Cancer
Location:
Texas Oncology-Amarillo Cancer Center
Phase: I
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Waldenström macroglobulinemia
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Waldenström macroglobulinemia
Location:
Texas Oncology-Amarillo Cancer Center
Phase: II